COVID-19 Outbreak Information – Click here for the latest updates INVESTORS MEDIA ABOUT US INNOVATION AND TECHNOLOGY OUR STORIES CONTACT & QUOTATION REQUEST CAREERS SERVICES GENERIC PEPTIDES COMMERCIAL MANUFACTURING CUSTOM R&D COSMETIC INDIVIDUALIZED PEPTIDES OLIGOS INVESTORS Interactive Share Price Chart PolyPeptide Group is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide’s shares (PPGN) are listed on the Swiss Stock Exchange SIX. INVESTORS Share Information Corporate News Analyst Coverage Results Center Corporate Calendar Presentations Corporate Governance Initial Public Offering IR Contact ABOUT US HISTORY INNOVATION & TECHNOLOGY OUR STORIES BROCHURES VIDEOS POLYPEPTIDE GROUP INFO INVESTORS CORPORATE NEWS OUR STORIES ABOUT US MEDIA CONTACT CONTACT US QUOTATION REQUEST CAREERS SOCIALS LINKEDIN FACEBOOK TWITTER YOUTUBE © Confidentiality 2021 PolyPeptide Group Cookie management Personal data Sitemap ACTH (1-39) Porcine Atosiban Calcitonin Carbetocin Deslorelin Desmopressin Exenatide Felypressin Leuprolide Liraglutide Octreotide PTH (1-34) Teriparatide Semaglutide Somatostatin Triptorelin Vasopressin, 8-L-Arginine